Fineotex Chemical Share Price Crashes 90%: What Investors Should Know

In a stunning turn of events, Fineotex Chemical Ltd's share price plunged nearly 90% on October 31, 2025. Opening at ₹25.25 on the NSE, down from the previous day's close of ₹248.60, the dramatic drop left investors and market analysts astounded. However, the sharp decline is attributed to corporate actions rather than any fundamental issues with the company.

Understanding the Corporate Actions

The significant drop in Fineotex Chemical's stock price is a result of two key corporate actions:

• Stock Split: The company implemented a 1:2 stock split, reducing the face value of each share from ₹2 to ₹1.

• Bonus Issue: A 4:1 bonus issue was declared, meaning shareholders received four additional shares for every one share held.

These adjustments are standard procedures aimed at enhancing share liquidity and making the stock more affordable to retail investors. However, such corporate actions often lead to a temporary drop in share price, as observed in this instance.

MORE ARTICLES:

• ASX Falls as Inflation Shock Dashes Rate Cut Hopes

• Today’s Top U.S. Trends: PayPal Stock Jump, ICE Arrests Spike, and Austin Tice Case Update (Oct 28, 2025)

• Canada’s Gold Investment at Risk—Act Fast!

Adjusted Share Price

When accounting for the stock split and bonus issue, the adjusted share price stands at ₹26.95, reflecting an increase of 8.45% from the previous close. This adjustment clarifies that the apparent 90% drop is a result of corporate action adjustments and not a reflection of the company's financial health.

 Market Implications

While the sharp decline in share price may have caused initial concern among investors, it's important to understand that such fluctuations are common following corporate actions. The adjustments are designed to make the stock more accessible to a broader base of retail investors, potentially leading to increased market participation in the long term.

Disclaimer:
This article is intended for informational purposes only and does not constitute investment advice. Procapitas does not provide personalized financial recommendations. Always consult a licensed financial advisor before making investment decisions. Information is based on publicly available sources as of June 2025 and Procapitas’ independent research and analysis.